DiaMedica Therapeutics (DMAC) Price to Book (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Price to Book for 9 consecutive years, with 9.9 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book rose 60.16% year-over-year to 9.9; the trailing twelve-month figure through Jun 2026 stood at 9.9 (up 60.16% YoY), and the FY2025 full-year result was 7.62, up 33.52% from the prior year.
• Price to Book improved to 9.9 in Q2 2026 per DMAC's latest filing, from 7.72 in the prior quarter.
• Across five years, Price to Book topped out at 9.9 in Q2 2026 and bottomed at 0.93 in Q3 2022.
• Historically, Price to Book has averaged 3.88 across 5 years, with a median of 2.31 in 2024.
• The sharpest annual moves came in 2022 and 2024: Price to Book slumped 78.17% in 2022, then jumped 170.45% in 2024.
• Over 5 years, Price to Book stood at 1.31 in 2022, then jumped by 60.84% to 2.11 in 2023, then surged by 170.45% to 5.71 in 2024, then jumped by 33.52% to 7.62 in 2025, then climbed by 29.88% to 9.9 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 9.9, 7.72, and 7.62 for Q2 2026, Q1 2026, and Q4 2025 respectively.